0.9488

0.95% 0.0089

After Hours: .96 0.0112 +1.18%

Clearmind Medicine Inc (CMND)

Overview News Price History Why CMND Down? Discussions Forecast Stock Split

Clearmind Medicine Inc stock is traded at $0.9488, with a volume of 153.69K. It is up +0.95% in the last 24 hours and down -1.17% over the past month. Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Previous Close:

$0.9399

Open:

$0.94

24h Volume:

153.69K

Relative Volume:

0.67

Market Cap:

$4.94M

Revenue:

Net Income/Loss:

$-6.78M

P/E Ratio:

-0.0222

EPS:

-42.6996

Net Cash Flow:

$-4.67M

1W Performance:

-1.37%

1M Performance:

-1.17%

6M Performance:

-30.74%

1Y Performance:

-8.93%

1-Day Range:

$0.9144

$1.05

1-Week Range:

$0.891

$1.05

52-Week Range:

$0.85

$2.30

Clearmind Medicine Inc Stock (CMND) Company Profile

Name

Clearmind Medicine Inc

Sector

Healthcare (1170)

Industry

Biotechnology (667)

Phone

Address

Employee

Twitter

Next Earnings Date

Latest SEC Filings

CMND's Discussions on Twitter

Compare CMND with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CMND Clearmind Medicine Inc	0.9488	4.94M	0	-6.78M	-4.67M	-42.70
VRTX Vertex Pharmaceuticals Inc	450.50	113.52B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	493.22	52.93B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	300.83	39.71B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	585.93	35.00B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	255.86	26.57B	3.81B	-644.79M	-669.77M	-6.24

Clearmind Medicine Inc Stock (CMND) Latest News

Jun 05, 2025

Clearmind Medicine Announces Enrollment Of First Patient In Phase I/Iia Clinical Trial For Alcohol Use Disorder Treatment - marketscreener.com

Jun 05, 2025

Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment - The Manila Times

Jun 05, 2025

Clearmind Medicine Inc. Begins Phase I/IIa Trial for CMND-100 to Treat Alcohol Use Disorder - Nasdaq

Jun 05, 2025

May 30, 2025

SciSparc Ltd. Announces European Patent Application for Cocaine Addiction Treatment in Collaboration with Clearmind Medicine Inc. - Nasdaq

May 12, 2025

Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction - The Manila Times

May 12, 2025

SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction - The Manila Times

May 12, 2025

Apr 28, 2025

Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight - GlobeNewswire Inc.

Apr 28, 2025

Apr 25, 2025

Clearmind Medicine files patent for eating disorder treatment - Investing.com

Apr 25, 2025

SciSparc and Clearmind file patent for eating disorder treatment - Investing.com

Apr 25, 2025

Clearmind Medicine files patent for eating disorder treatment By Investing.com - Investing.com South Africa

Apr 25, 2025

SciSparc and Clearmind file patent for eating disorder treatment By Investing.com - Investing.com India

Apr 25, 2025

Psychedelic: Clearmind completes clinical site initiations for AUD trial - Yahoo Finance

Apr 25, 2025

SciSparc and Clearmind File Patent for Eating Disorder Treatment - TipRanks

Apr 25, 2025

Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders - The Manila Times

Apr 25, 2025

SciSparc-Clearmind Collaboration Leads to Filing of - GlobeNewswire

Apr 25, 2025

Clearmind Medicine Inc. Files International Patent for Novel Treatment of Eating Disorders Using 3-MMC and PEA - Nasdaq

Apr 25, 2025

Novel Eating Disorder Treatment Patent Filed for 70M Patient Market | SPRC Stock News - Stock Titan

Apr 25, 2025

Apr 23, 2025

Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites - The Manila Times

Apr 23, 2025

Clearmind Medicine Inc. Initiates Patient Enrollment for Phase I/IIa Clinical Trial in Alcohol Use Disorder - Nasdaq

Apr 23, 2025

Clearmind Medicine (NASDAQ:CMND) Stock Price Down 4.8% – Here’s Why - Defense World

Apr 23, 2025

Apr 22, 2025